CELL INTELLIGENCE · 肿瘤细胞治疗研究

携带显性负性 TGF-β 受体 II 的装甲双顺反子 CAR-T 细胞克服胶质母细胞瘤耐药

Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.

胶质母细胞瘤的 CAR-T 细胞治疗：克服当前障碍与提升疗效的策略及其治疗意义

Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications

CAR-T 细胞：治疗脑肿瘤及其他疾病的工程化免疫细胞

CAR T cells: engineered immune cells to treat brain cancers and beyond.

局部分泌的 BiTE 通过增强对抗原异质性实体瘤的杀伤补强 CAR-T 细胞

Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors.

含 CD28 跨膜结构域的 IL13Rα2 靶向第三代 CAR-T 细胞介导最佳抗胶质母细胞瘤疗效

IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.

推进胶质母细胞瘤免疫治疗：分子通路与创新治疗策略

Advancing glioblastoma immunotherapy: Molecular pathways and innovative therapeutic strategies.

胶质母细胞瘤 CAR-T 细胞治疗的全球研究趋势：一项文献计量学和可视化分析

Global research trends in CAR-T cell therapy for glioblastoma: a bibliometric and visualized analysis.

本研究描绘了 CAR-T 细胞治疗在 GBM 中不断演变的科学图景，凸显了关键贡献者、机构合作以及新兴研究前沿。

挑战与突破：实体瘤 CAR-T 细胞治疗临床试验的现状与未来前景

Challenges and breakthroughs: current landscape and future prospects of CAR-T cell therapy clinical trials for solid tumors.

CAR-T 细胞治疗胶质母细胞瘤的现状与进展

Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.

一种用于增强胶质母细胞瘤治疗的靶向 IL13Rα2 和 EphA2 的新型 TanCAR

A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy.